Associations that survived a Bonferroni procedure correction (0.05 level) were considered statistically significant
Projected Weight Loss by Starting Weight Based on Phase 3 data (12 mg dose, 68 weeks, 28.7% mean weight loss): averages based on the TRIUMPH-4 mean
Li N, Wang LJ, Jiang B, Guo SJ, Li XQ, Chen XC, et al
Leffers, N
Retatrutide Results: Weight Loss Data and What to Expect 28.3% average weight loss at 80 weeks in the pivotal Phase 3 trial here's the full data breakdown by dose, timeline, and what individual results look like
GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) and dulaglutide (Trulicity) can cause gastrointestinal side effects that may influence magnesium intake and absorption